EGFR and neoplasm: Thus, the dual functionality of CmAb-(IL-10)2 is based on Cetuximab in one arm to bind EGFR+ tumor cells and an IL-10 dimer in the other arm to bind and activate IL-10R-mediated signaling pathways [66].